M e d i c i n e A v e 2 Botulinum Toxin Type A There is help. To learn more about BOTOX efficacy and receive information regarding BOTOX treatment, please visit www.botox.com or call 1-800-433-8871. BOTOX*’ treatment is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any ingredient in the formulation. Serious and/or immediate hypersensitivity reactions have been rarely reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea. BOTOX® should only be diluted with 0.9% nonpreserved sodium chloride. Other diluents, including lidocaine, should not be used for reconstitution. Individuals with peripheral motor neuropathic diseases (eg, amyotrophic lateral sclerosis or motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should only receive BOTOX® treatment with caution. Patients with neuromuscular disorders may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of BOTOX? The most frequently reported adverse events (3%-1Q% of patients) following injection were injection-site pain and hemorrhage, non-axiliary sweating, infection, pharyngitis, flu syndrome, headache, ■=§! ALLERGAW fever, neck or back pain, pruritus, and anxiety. ©205Ai ergan. inc. irvine, ca92612 Please see adjacent page for brief summary of prescribing information. w bol ox. com Prior to 1997, any mention of "FDA approved" in an ad was forbidden by the FD&C Act, Sec. 301(1). That provision was eliminated by the FDA Modernization Act of 1997, and advertisers were quick to respond. 62
RkJQdWJsaXNoZXIy NDMwNDAx